Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Юниверсити Оф МонтанаfiledCriticalДзе Юниверсити Оф Монтана
Priority claimed from PCT/US2020/034258external-prioritypatent/WO2020237164A1/en
Publication of EA202193228A1publicationCriticalpatent/EA202193228A1/en
Липидированные оксоаденины формулы (I) представляют собой лиганды рецепторов TLR7/8, применимые для модулирования иммунных ответов. Соединения могут иметь терапевтическое применение в лечении рака, инфекционных заболеваний, аллергии или аутоиммунных нарушений.Lipidized oxoadenins of formula (I) are TLR7/8 receptor ligands useful for modulating immune responses. The compounds may have therapeutic use in the treatment of cancer, infectious diseases, allergies, or autoimmune disorders.
EA202193228A2020-02-112020-05-22
VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS
EA202193228A1
(en)
compound, pharmaceutical and vaccine composition, methods for inducing or promoting an immune response, for treating cancer, infectious diseases, immunological disorders and immunological diseases, and for treating or preventing a disease, and, using a compound
Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor.their use in the treatment of cancer.